WO2023275336A1 - Inhibitors of transglutaminases - Google Patents
Inhibitors of transglutaminases Download PDFInfo
- Publication number
- WO2023275336A1 WO2023275336A1 PCT/EP2022/068216 EP2022068216W WO2023275336A1 WO 2023275336 A1 WO2023275336 A1 WO 2023275336A1 EP 2022068216 W EP2022068216 W EP 2022068216W WO 2023275336 A1 WO2023275336 A1 WO 2023275336A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- cyclo
- carboxylic acid
- nhso
- bicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the invention relates to novel inhibitors of transglutaminases, in particular transglutaminase 2, methods for their synthesis and to their use for the prophylaxis and treatment of diseases associated with transglutaminases, in particular transglutaminase 2.
- Transglutaminases are part of the class of transferases and according to EC nomenclature they are correctly designated as “protein-glutamine: amine g-glutamyl transferases” (EC 2.3.2.13). They link the e-amino group of the amino acid lysine and the g-glutamyl group of the amino acid glutamine forming an isopeptide bond while ammonia is released. In the absence of suitable amines and/or under certain conditions, deamidation of the glutamine may occur resulting in the corresponding glutamic acid.
- transglutaminases play an important role in many therapeutic areas such as the cardiovascular diseases (thrombosis and atherosclerosis), autoimmune diseases (celiac disease, Duhring-Brocq-disease, gluten ataxia), neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, Huntington’s disease), dermatological diseases (ichthyosis, psoriasis, acne) as well as in wound healing and inflammatory diseases (e.g. tissue fibrosis) (J.M. Wodzinska, Mini-Reviews in medical chemistry, 2005, 5, 279 - 292).
- cardiovascular diseases thrombosis and atherosclerosis
- autoimmune diseases celiac disease, Duhring-Brocq-disease, gluten ataxia
- neurodegenerative diseases Alzheimer’s disease, Parkinson’s disease, Huntington’s disease
- dermatological diseases ichthyosis, psoriasis, acne
- wound healing and inflammatory diseases e.g. tissue
- Celiac disease a gluten intolerance, however, is one of the most important indications.
- Celiac disease is characterized by a chronic inflammation of the mucosa of the small intestine.
- the intestinal epithelium is successively destroyed after ingestion of gluten-containing food resulting in reduced absorption of nutrients which again has massive impact on the patients affected and is for example associated with symptoms such as loss of weight, anemia, diarrhea, nausea, vomiting, loss of appetite and fatigue. Due to these findings, there is a large demand for the development of a medicament for the treatment of celiac disease as well as of other diseases associated with tissue transglutaminase (transglutaminase 2, TG2, tTG).
- tissue transglutaminase is a central element during pathogenesis.
- the endogenous enzyme catalyses the deamidation of gluten/gliadin in the small intestinal mucosa and thus triggers the inflammatory response. Therefore inhibitors of tissue transglutaminase are suitable to be used as active agents for medication.
- Another very important group of indications for tissue transglutaminase inhibitors are fibrotic disorders. Fibrotic disorders are characterized by the accumulation of cross- linked extracellular matrix proteins. Diabetic nephropathy, cystic fibrosis, idiopathic pulmonary fibrosis, kidney fibrosis as well as liver fibrosis belong to the most important fibrotic disorders to be addressed with the compounds disclosed.
- US 9,434,763 B2 discloses pyridinone derivatives having a warhead comprising at least one acceptor-substituted double bond, such as a Michael System, as irreversible transglutaminase inhibitors.
- Alkylacetamido and arylacetamido pyridinones showed inhibitory activity regarding tissue transglutaminase TG2 in nanomolar range (IC 50 ).
- US 11 ,072,634 B2 discloses reversible transglutaminase inhibitors comprising an aldehyde, a ketone, an a-ketoaldehyde, an a-ketoketone, an a-ketoacid, an a-ketoester, an ⁇ -ketoamide or a halogenmethylketone as warhead.
- the inhibitors showed inhibitory activity regarding tissue transglutaminase TG2 in nanomolar and micromolar range (IC 50 ) ⁇
- the objective of the present invention is to provide novel, most probably reversible inhibitors of transglutaminases, in particular transglutaminase 2 and methods for the synthesis of said inhibitors as well as several uses of these inhibitors.
- transglutaminase 2 tissue transglutaminase 2 or TG2.
- transglutaminase 2 tissue transglutaminase 2
- such chemical warhead moiety is particularly selected from reversible warheads such as a-ketoamides.
- the compounds of the present invention act as selective inhibitors of transglutaminase 2.
- branched alkyl moieties as lead structures, such excluding aromatic moieties, e.g. the phenyl group.
- bridged cycloalkyl groups are non-classical bioisosters of the phenyl group.
- a skilled person would expect similar physico-chemical or biochemical properties excluding to invest efforts. Since aromatic moieties are clearly not preferred, bridged cycloalkyl groups would not be considered improving the compounds.
- ZED3641 (Ref. 1 , as disclosed in US 11 ,072,634 B2; reversible acting a-ketomethylamide analogue to Ref. 2, ZED1227) is about 15-fold more potent compared to Ref. 4 (compare table 1).
- Ref. 4 is analogous to compound A8 disclosed in US 9,434,763 B2 with respect to the backbone proving again superiority of branched alkyl moieties compared to aromatic derivatives in combination with reversible acting warheads.
- inventive compounds rated “A” show efficacies of about 30-fold higher compared to Ref. 3 (A8, compare to tablel).
- L represents -L 1 -L 2 -;
- L 1 represents -CH 2 - -CH2CH2-, -CH2CH2CH2-, -CH 2 CO-, or
- L 2 represents a bond, -NR N1 - -NR N1 CH 2 - -NR N1 CH 2 CH 2 - or -NR N1 CH(CH 3 )-
- R 1 represents
- R 2 represents
- unsubstituted bicyclic residues can be substituted with 1 to 5 of the substituents R 9 - R 14 , and R N and preferably with 1 to 3 of the substituents R 11 - R 13 ;
- R a , R b , R c , R d , and R e represents independently of each other -H, -F, -Cl, -Br, -CN, -OH, -CH 3 , -CH2CH3, -CH2CH2CH3, -CH(CH 3 ) 2 , -CHF 2 , -CF 3 , -CH2CF3, -COCH3, -COCH2CH3, -CO2H, -CO2CH3, -CO2C2H5, -CONH2,
- R 4 represents -NR 6 R 7 ;
- R 6 represents -CH 2 CH 3
- R 7 represents -H
- R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , and R 14 represent independently of each other -H, -F, -Cl, -Br, -I, -OH, -CN, -NO 2 , -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -C 4 H 9 , -CH 2 ⁇ CH(CH 3 ) 2 , -CH(CH 3 ) -C 2 H 5, -C(CH 3 ) 3 , -cyclo-C 3 H 5 , -CH 2 -cyclo -C 3 H 5 , -CH 2 F, -CHF 2 , -CF 3 , -CH 2 Cl, -CH 2 Br, -CH 2 I, -CH 2 -CH 2 F, -CH 2 -CHF 2 , -CH 2 -CF 3 , -CH 2 -CH 2 Cl,
- R N represents -H, -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -C 4 H 9 ,
- R N1 represent -H, -CH 3 , or -CH 2 CH 3 ; or a diastereomer, an enantiomer, a mixture of diastereomers, a mixture of enantiomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof.
- inhibition data were determined using the classical fluorescent transamidation assay (dansylcadaverine incorporation into methylated casein, DCC- assay) as described in Buchold et al. [Buchold, C.; Hils, M.; Gerlach, U.; Weber, J.; Pelzer, C.; Heil, A.; Aeschlimann, D.; Pasternack, R.
- ZED1227 The First-In- Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease. Cells 2022, 11, 1667. https://doi.org/10.3390/cells11101667].
- Casein is one of the best known high molecular weight (24 kDa) protein substrates for transglutaminases.
- Inhibition data of the inventive compounds was compared with inhibition of compounds disclosed in US 9,434,763 B2, particularly, compound A8, which is denoted herein as Reference 3. It is noteworthy that the IC 50 values of compounds A8 published in US 9,434,763 B2 and E16 from US 11 ,072,634 B2 cannot be compared to the present data, relying on a fluorogenic isopeptidase assay.
- inventive compounds of formula (I) rated “A” showed efficacies of about 100- fold higher compared to Ref. 3 (A8).
- Ref. 4 shows also that aromatic moiety of this reference comopund reduces the inhbibitory activity against TG2 strongly.
- inventive compounds demonstrate that bridged cycloalkyl groups improve the potency of the compounds by orders of magnitude compared to the aromatic reference compounds. Therefore, we credit bridged cycloalkyl groups as disclosed with an outstanding inventive manner.
- R 2 represents
- the unsubstituted bicyclic residues can be substituted with 1 to 5 of the substituents R 9 - R 14 , and R N ; and preferably with 1 to 3 of the substituents R 11 - R 13 ; and the substituents R 9 -R 14 , and R N have the meanings as defined informula (I); and more preferably R 2 represents wherein the unsubstituted bicyclic residues can be substituted with 1 to 5 of the substituents R 9 - R 14 and R N ; and preferably with 1 to 3 of the substituents R 11 - R 13 ; and the substituents R 9 -R 14 and R N have the meanings as defined herein.
- the unsubstituted bicyclic residues which can be substituted with 1 to 5 of the substituents R 9 - R 14 and R N ; have the following structure and the substituents R 9 - R 14 and R N have the meanings as defined herein:
- L represents -L 1 -L 2 - ;
- L 1 represents -CH 2 CO-
- R 1 represents
- R 2 represents R 6 represents -C 2 H 5 ;
- R a , R b , R c , R d , and R e represents independently of each other -H, -F, -Cl, -Br, -CN, -OH, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CHF 2 , -CF 3 ,
- R 8 , R 10 , and R 11 represent independently of each other
- R N represents -H, -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -C 4 H 9 ,
- R N1 represent -H, -CH 3 , or -CH 2 CH 3 ; or a diastereomer, an enantiomer, a mixture of diastereomers, a mixture of enantiomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof.
- R 2 represents and R 8 , R 10 , R 11 , and R N have the meanings as defined herein.
- the present invention relates to the comopund of the formula (I) wherein
- L represents -L 1 -L 2 - ;
- L 1 represents -CH 2 - -CH 2 CH 2 - -CH 2 CH 2 CH 2 - or -CH 2 CO-
- L 2 represents -NR n1 - or -NR N1 CH 2; ; and preferably L represents -CH 2 - -CH 2 CH 2 - -CH 2 CH 2 CH 2 -
- R 1 represents
- R 2 represents
- R 3 represents bicyclo[1 .1 .1]pentan-1 -yl, bicyclo[2.1 1]hexan-1 -yl, bicyclo[3.1 .1 ]heptan-3-yl, bicyclo[2.2.1 ]heptan-2-yl, bicyclo[2.2.1 ]hept-5-en-2-yl, bicyclo[2.2.1]heptan-7-yl, bicyclo[2.2.1]heptan-2-yl, bicyclo[2.2.2]octan-2-yl, 1 - adamantyl, 2-adamantyl , 4-homoisotwistyl, 1 -diamantyl, or 4-diamantyl, and the afore-mentioned bicyclo[1 .1 .1]pentan-1 -yl, bicyclo[2.1 1]hexan-1 -yl, bicyclo[3.1 .1 ]heptan-3-yl, bicycl
- R 6 represents -C 2 H 5 ; and R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R a , R b , R c , R d , R e , R N and R N1 have the same meanings as defined in formula (I) or a diastereomer, an enantiomer, a mixture of diastereomers, a mixture of enantiomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof.
- the present invention relates to the comopund of the formula (I) wherein
- L represents -L 1 -L 2 - ;
- L 1 represents -CH 2 CO-
- R 1 represents
- R 2 represents
- R 6 represents -C 2 H 5 ; and R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R a , R b , R c , R d , R e , R N and R N1 have the same meanings as defined in formula (I) or a diastereomer, an enantiomer, a mixture of diastereomers, a mixture of enantiomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof.
- the present invention relates to the comopund of the formula (I) wherein
- L represents -L 1 -L 2 - ;
- L 1 represents -CH 2 CO-
- R 1 represents
- R 2 represents
- R 6 represents -C 2 H 5 ; and R 8 , R 10 , R 11 , R a , R b , R c , R d , R e , R N and R N1 have the same meanings as defined in formula (I) or a diastereomer, an enantiomer, a mixture of diastereomers, a mixture of enantiomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof.
- the present invention relates to the compound of the formula (la): wherein
- L represents -L 1 -L 2 - ;
- L 1 represents -CH 2 CO-
- R 2 represents
- R 6 represents -C 2 H 5 ;
- R a , R b , R c , R d , and R e represents independently of each other -H, -F, -Cl, -Br, -CN, -OH, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CHF 2 , -CF 3 ,
- R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , and R 14 represent independently of each other -H, -F, -Cl, -Br, -I, -OH, -CN, -NO 2 ,
- R N represents -H, -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -C 4 H 9 ,
- R N1 represents -H, -CH 3 , or -C 2 H5; or a diastereomer, an enantiomer, a mixture of diastereomers, a mixture of enantiomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof.
- the present invention relates to the compound of the formula (la): wherein
- L represents -L 1 -L 2 - ;
- L 1 represents -CH 2 CO-
- R 2 represents
- R 6 represents -C 2 H5;
- R a , R b , R c , R d , and R e represents independently of each other -H, -F, -Cl, -Br, -CN, -OH, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CHF 2 , -CF 3 ,
- R 8 , R 10 , and R 11 represent independently of each other
- R N represents -H, -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -C 4 H 9 ,
- R N1 represents -H, -CH 3 , or -C 2 H5; or a diastereomer, an enantiomer, a mixture of diastereomers, a mixture of enantiomer, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof.
- the compound of the invention has the formula (II): wherein
- L 2 represents -NR n1 -, and R 3 represents 1-adamantyl
- L 2 represents -NR N1 CH 2 -
- R 3 represents 2-bicyclo[3.1.1 ]heptyl
- R 2 represents
- R a , R b , R c , R d , and R e represents independently of each other -H, -F, -Cl, -Br, -CN, -OH, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CHF 2 , -CF 3 ,
- R N represents -H, -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -C 4 H 9 , -CH 2- CH(CH 3 ) 2 , -CH(CH 3 )-C 2 H 5, -C(CH 3 ) 3 , -cyclo-C 3 H 5 , -cyclo-C 4 H 7 ,
- R n1 represent -H, -CH3, or -CH2CH3;
- R 8 , R 10 , and R 11 represent independently of each other
- 2-bicyclo[3.1 .1 ]heptyl have the following structure: and R a and R b , have the same meanings as defined herein.
- the compound has any one of the formulae (ll-a) - (ll-l), (ll-b1 ) - (Il-b2), and (lll-a) - (lll-l):
- L 1 , L 2 , R 2 , R N , R a , R b , R c , R d and R e have the same meanings as defined in the formula (I), preferred in the formula (la) , more preferred in the formula (II).
- L 1 , L 2 , R 8 , R 10 , R 11 , R 12 , R 13 , R 11 , R N , R a , R b , R c , R d and R e have the same meanings as defined in the formula (I), preferred in the formula (la).
- the invention refers to the compound of the formulae (I), (la) and (II), wherein R 3 represents
- R 3 represents in a preferred embodmiment, the invention refers to the compound of any one of the formulae (I), (la) and (II), (ll-a) - (ll-l), (ll-bl) - (Il-b2), wherein
- R 2 represents wherein
- R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , and R 14 represent independently of each other -H, -F, -Cl, -Br, -I, -OH, -CN, -NO 2 ,
- R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , and R 14 represent independently of each other -H, -F, -Cl, -Br, -OH, -CN, -NO 2 ,
- R N represents -H, -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -C 4 H 9 ,
- R N represents -H, -CH 3 , -C 2 H 5 , -CH(CH 3 ) 2 , -cyclo-C 3 H 5 ,
- R N represents -H, -CH 3 , -C 2 H 5 , -
- the invention refers to the compound of any one of the formulae (I), (la) and (II), (ll-a) - (ll-l), (ll-bl ) - (Il-b2), R 2 represents
- R 2 represents Still more preferred, R 2 represents
- the invention refers to the compound of any one of the formulae (I), (la) and (II), (ll-a) - (ll-l), (ll-bl) - (Il-b2), wherein
- L represents -CH 2 - -CH 2 CH 2 - -CH 2 CH 2 CH 2 - -CH 2 CONH- -CH 2 CONH-CH 2 - -CH 2 CON(CH 3 )-CH 2 - -CH 2 CONH-CH(CH 3 )-,
- the present invention relates to a method for the synthesis of a compound of formula (I), especially any compound of the formula (la): As shown in Scheme 1 , a method for producing the compound of the formula (la) comprising:
- Step 1A providing a compound 4a
- Step 2A performing coupling reaction of the compound 4a with a compound 5 to obtain a compound 6a
- Step 3A deprotecting an 3 amino protecting group PG to obtain a compound 7a
- Step 4A performing coupling reaction of the compound 7a with a carboxylic acid (R 2 -CO 2 H 8) to obtain a compound 9a
- Step 5A performing oxidation reaction of the compound 9a to produce the compound of the formula (la) wherein L, R 2 , R 3 ,and R 6 have the same meanings as defined above in formula
- PG 3 is an amino protecting group.
- Step 1A ' is carried out before the step 1A: (a) providing a protected aldehyde 1
- PG 1 and PG 3 are amino protecting groups
- PG 2 is a carboxyl protecting group
- Step 1A ' (a) providing a protected aldehyde 1
- Step 1A providing a compound 4a
- Step 2A performing coupling reaction of the compound 4a with a compound 5 to obtain a compound 6a
- Step 3A deprotecting the amino protecting group PG 3 to obtain a compound 7a
- Step 4A performing coupling reaction of the compound 7a with a carboxylic acid (R 2 -CO 2 H 8) to obtain a compound 9a
- Step 5A performing oxidation reaction of the compound 9a to produce the compound of the formula (la) wherein L, R 2 , R 3 ,and R 6 have the same meanings as defined above in the formula (la), and PG 1 and PG 3 are amino protecting groups,
- PG 2 is a carboxyl protecting group.
- first all protecting groups PG 1 and PG 2 are simultaneously removed and the protecting group PG 3 is selectively introduced.
- PG 1 and PG 3 are same.
- protecting groups refers to commonly used protection groups in organic synthesis, preferably for amino and carboxyl groups.
- PG 1 , PG 3 , and PG 5 preferably are suitable protecting groups for amino groups.
- PG 2 and PG 4 preferably are suitable protecting groups for carboxyl groups.
- PG 1 , PG 3 , and PG 5 may be selected from the group consisting of or comprising: acetyl, benzoyl, benzyloxycarbonyl (Cbz), tert-butylcarbonyl, tert-butyloxycarbonyl (Boc), and fluorenylmethylenoxy group (Fmoc).
- PG 2 and PG 4 may be selected from the group consisting of or comprising: methoxy, ethoxy, isobutoxy, tert-butoxy, benzyloxy; preferably, tert-butoxy group.
- activating reagents are commonly used to activating carboxylic acid reminderPeptide Coupling Reagents, More than a Letter Soup", Ayman El-Faham and Fernando Albericio, Chemical Reviews, 2011 , 111(11), p.6557-6602).
- the activation may be introduced separate reaction or in situ reaction.
- any of the following coupling reagent can be used to activate carobxylic acid group: BOP (Benzotriazole-1 - yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate), PyBOP (Benzotriazole- 1 -yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate), AOP (7-(Azabenzotriazol- 1 -yl)oxy tris(dimethylamino)phosphonium hexafluorophosphate), PyAOP ((7- Azabenzotriazol-1 -yloxy)tripyrrolidinophosphonium hexafluorophosphate), TBTU (2-(1 H- Benzotriazole-1 -yl)-1 ,1 ,3,3-tetramethylaminium tetrafluoroborate), EEDQ ( N - Ethoxycarbonyl-2-ethoxy
- Another aspect of the present invention relates to compounds according to the general formula (I) as medicine as well as their use in medicine. Especially preferred is the use as inhibitors of transglutaminases, in particular transglutaminsase 2 (TG2).
- TG2 transglutaminsase 2
- the compounds of the present invention may form of a pharmacologically acceptable salt with organic or inorganic acids or bases.
- suitable acids for such acid addition salt formation are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, salicylic acid, p-aminosalicylic acid, malic acid, fumaric acid, succinic acid, ascorbic acid, maleic acid, sulfonic acid, phosphonic acid, perchloric acid, nitric acid, formic acid, propionic acid, gluconic acid, lactic acid, tartaric acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, methanesulfonic acid, ethanesulfonic acid, nitrous acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, p
- the salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner.
- Preferred is the mesylate salt, hydrochloride salt and the trifluoroacetate salt and especially preferred is the trifluoroacetate salt and the hydrochloride salt.
- salts could also be formed with inorganic or organic bases.
- suitable inorganic or organic bases are, for example, NaOH, KOH, NH 4 OH, tetraalkylammonium hydroxide, lysine or arginine and the like.
- Salts may be prepared in a conventional manner using methods well known in the art, for example by treatment of a solution of the compound of the general formula (I) with a solution of an acid, selected out of the group mentioned above.
- novel compounds according to the general formula (I) are used as pharmaceutically active agent, i.e. the compound of the formula (I) is used in medicine.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising at least one compound according to the general formula (I), as an active ingredient or a pharmacologically acceptable salts thereof as an active ingredient, together with at least one pharmacologically acceptable carrier, excipient and/or diluent.
- the compounds according to general formula (I) described herein are especially suitable for the treatment and prophylaxis of diseases associated with and/or caused by transglutaminase 2.
- tissue transglutaminase TG 2
- fibrotic disorders are characterized by the accumulation of cross- linked extracellular matrix proteins. Diabetic nephropathy, cystic fibrosis, idiopathic pulmonary fibrosis, kidney fibrosis as well as liver fibrosis belong to the most important fibrotic disorders to be addressed with the compounds disclosed.
- inhibiting refers to the ability of a compound to downregulate, decrease, reduce, suppress, inactivate, or inhibit at least partially the activity of an enzyme, or the expression of an enzyme or protein.
- another aspect of the present invention is the use of the inventive compounds of the general formula (I), or the pharmaceutical composition thereof as described in the treatment or prophylaxis of autoimmune and inflammatory diseases, vascular diseases, fibrotic diseases, liver diseases, cholestatic liver diseases, cancer, neurodegenerative diseases, ocular diseases, and skin disorders.
- Further aspects of the present invention relate to the use of the compounds of general formula (I) for the preparation of a pharmaceutical composition useful for prophylaxis and/or treatment of autoimmune and inflammatory diseases, vascular diseases, fibrotic diseases, liver diseases, cholestatic liver diseases, cancer, neurodegenerative diseases, ocular diseases, and skin disorders.
- a method for preventing and/or treating autoimmune and inflammatory diseases, vascular diseases, fibrotic diseases, liver diseases, cholestatic liver diseases, cancer, neurodegenerative diseases, ocular diseases, and skin disorders comprises administering to a subject, in particular a human, a pharmaceutically effective amount of at least one compound of the general formula (I), to prevent and/or treat said autoimmune and inflammatory diseases, vascular diseases, fibrotic diseases, liver diseases, cholestatic liver diseases, cancer, neurodegenerative diseases, ocular diseases, and skin disorders.
- the autoimmune and inflammatory diseases comprises multiple sclerosis, celiac disease, Duhring-Brocq-disease (dermatitis herpetiformis), gluten ataxia, gluten neuropathy, diabetes, rheumatoid arthritis, Graves' disease, inflammatory bowel disease, systemic lupus erythematosus psoriasis, and gingivitis;
- the vascular diseases comprise atherosclerosis, thrombosis, vascular stiffness;
- the compound of the formula (I), or the pharmaceutical composition thereof is useful in the treatment or prophylaxis of celiac disease.
- the compounds of the general formula (I) can be administered in form of their pharmaceutically active salts, optionally using essentially non-toxic pharmaceutically acceptable carriers, adjuvants or extenders.
- Medications are prepared in a known manner in a conventional solid or fluid carrier or in extenders and a conventional pharmaceutically acceptable adjuvant/expedient in a suitable dose.
- the preferred preparations are provided in an administrable form suitable for oral application, such as pills, tablets, film tablets, coated tablets, capsules and powders.
- Tablets, film tablets, coated tablets, gelatin capsules and opaque capsules are the preferred pharmaceutical formulations.
- Any pharmaceutical compositions contains at least one compound of the general formula (I), and/or pharmaceutically acceptable salts thereof in an amount of 5 mg to 500 mg, preferably 10 mg to 250 mg and most preferred in an amount of 10 to 100 mg per formulation.
- the object of the present invention also includes pharmaceutical preparations for oral, parenteral, dermal, intradermal, intragastric, intracutaneous, intravascular, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal, percutaneous, rectal, subcutaneous, sublingual, topic, transdermal or inhalative application, containing, in addition to typical vehicles and extenders, a compound of the general formula (I), and/or a pharmaceutically acceptable salt thereof as active component.
- pharmaceutical preparations for oral, parenteral, dermal, intradermal, intragastric, intracutaneous, intravascular, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal, percutaneous, rectal, subcutaneous, sublingual, topic, transdermal or inhalative application containing, in addition to typical vehicles and extenders, a compound of the general formula (I), and/or a pharmaceutically acceptable salt thereof as active component.
- compositions of the present invention contain one of the compounds of the formula (I) disclosed herein as active component, typically mixed with suitable carrier materials, selected with respect to the intended form of administration, i.e. tablets to be administered orally, capsules (filled either with a solid, a semi-solid or a liquid), powders, orally administrable gels, elixirs, dispersible granulates, syrups, suspensions and the like in accordance with conventional pharmaceutical practices.
- suitable carrier materials selected with respect to the intended form of administration, i.e. tablets to be administered orally, capsules (filled either with a solid, a semi-solid or a liquid), powders, orally administrable gels, elixirs, dispersible granulates, syrups, suspensions and the like in accordance with conventional pharmaceutical practices.
- the compound of the formula (I) can as active agent component be combined with any oral, non-toxic, pharmaceutically acceptable, inert carrier, such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid forms) and the like for the oral administration in form of tablets or capsules.
- suitable binders, lubricants, disintegrants and colorants can be added to the mixture if required.
- Powders and tablets can consist of said inert carriers to an extent from about 5% per weight to about 95% per weight of the inventive composition.
- Suitable binders include starch, gelatin, natural sugars, sweeteners made of corn, natural and synthetic gums, such as acacia gum, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes.
- Possible lubricants for the use in said dosage forms include boric acid, sodium benzoate, sodium acetate, sodium chloride and the like.
- Disintegrants include starch, methylcellulose, cyclodextrins, guar gum and the like. If required, sweeteners and flavor additives and preservatives can also be included.
- compositions of the present invention can be formulated in a form with sustained release to provide a controlled release rate of any one or more components or active components, in order to optimize the therapeutic effect, i.e. the inhibitory activity and the like.
- Suitable dosage forms for sustained release include layered tablets containing layers with varying degradation rates or controlled release polymeric matrices impregnated with the active components and in the form of a tablet or capsule containing such impregnated or encapsulated porous polymeric matrices.
- Preparations in fluid form include solutions, suspensions and emulsions.
- solutions include solutions, suspensions and emulsions.
- exemplary mentioned are water or water propylene glycol solutions for parenteral injections or the addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions.
- Aerosol preparations suitable for inhalation may include solutions and solids in the form of powders which can be combined with a pharmaceutically acceptable carrier, such as a compressed inert gas, e.g. nitrogen.
- a pharmaceutically acceptable carrier such as a compressed inert gas, e.g. nitrogen.
- a low melting wax such as a mixture of fatty acid glycerides, e.g. cocoa butter
- the active component is homogenously dispersed therein by stirring or similar mixing operations.
- the melted homogenous mixture is then poured in fitting forms, cooled and thus hardened.
- preparations in solid form which are to be converted into preparations in fluid form for either oral or parenteral administration shortly before use are included.
- fluid forms include solutions, suspensions and emulsions.
- the compounds of the present invention may be administered via transdermal application.
- the transdermal compositions can have the form of cremes, lotions, aerosols and/or emulsions.
- capsule refers to a special container or casing composed of methylcellulose, polyvinyl alcohols or denatured gelatins or starches, in which the active agents can be enclosed.
- hard shell capsules are prepared from mixtures of bones and porcine skin gelatins having comparatively high gel strength.
- the capsule itself can contain small amounts of colorants, opacifiers, softening agents and preservatives.
- Tablet means a compressed or cast solid dosage form containing the active components with suitable extenders.
- the tablet can be produced by compressing mixtures or granulates obtained by wet granulation, dry granulation or compaction, which are known to the one skilled in the art.
- Oral gels refer to the active components dispersed or solubilized in a hydrophilic semi solid matrix.
- Powders for compositions refer to powder mixtures containing the active components and suitable extenders which can be suspended in water or juices.
- Suitable extenders are substances which usually form the largest part of the composition or dosage form. Suitable extenders include sugars such as lactose, sucrose, mannitol and sorbitol; starches derived from wheat, corn, rice and potatoes; and celluloses such as microcrystalline cellulose.
- the amount of extenders in the composition can range from about 5 to about 95% per weight of the total composition, preferably form about 25 to about 75% per weight and further preferred from about 30 to about 60% per weight.
- disintegrants refers to materials added to the composition in order to support disintegration and release of the medicinal substance.
- Suitable disintegrants include starches, modified starches which are soluble in cold water, such as sodium carboxymethyl starch; natural and synthetic gums such as locust bean gum, caraya, guar gum, tragacanth and agar; cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose, microcrystalline celluloses and crosslinked microcrystalline celluloses such as croscarmellose sodium; alginates such as alginic acid and sodium alginate; clays such as bentonites and foaming mixtures.
- the amount of disintegrants used in the composition can range from about 2 to 20% per weight of the composition and further preferred from about 5 to about 10% per weight.
- Binders characterize substances binding or "gluing" powders to each other and they consequently serve as “glue” in the formulation. Binders add a cohesion starch which is already available in the extenders or the disintegrant. Suitable binders include sugar, such as sucrose; starches derived from wheat, corn, rice and potatoes; natural gums such as acacia gum, gelatin and tragacanth; derivatives of sea weed such as alginic acid, sodium alginate and ammonium calcium alginate, cellulose materials such as methyl cellulose and sodium carboxymethylcellulose and hydroxypropyl methylcellulose, polyvinylpyrrolidone and inorganic compounds, such as magnesium aluminum silicate.
- sugar such as sucrose
- starches derived from wheat, corn, rice and potatoes natural gums such as acacia gum, gelatin and tragacanth
- derivatives of sea weed such as alginic acid, sodium alginate and ammonium calcium alginate
- cellulose materials such as methyl
- the amount of binders in the composition can range from about 2 to about 20% per weight of the total composition, preferably form about 3 to about 10% per weight and further preferred from about 3 to about 6% per weight.
- lubricant refers to a substance added to the dosage form in order to allow for the tablet, granulate, etc. to be released from the casting mold or pressing mold, after compression, by reducing the friction. Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate or potassium stearate; stearic acid; waxes with high melting points and water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and D,L-leucine.
- lubricants Due to the fact that lubricants have to be present on the surface of the granulates as well as between the granulates and parts of the tablet press they are typically added during the last step prior to compression.
- the amount of lubricants in the composition can range from about 0.2 to about 5% per weight of the total composition, preferably form about 0.5 to about 2% per weight and further preferred from about 0.3 to about 1.5 % per weight.
- Lubricants are materials preventing caking and improving the flow characteristics of granulates so that the flow is smooth and uniform.
- Suitable lubricants include silicon dioxide and talc.
- the amount of lubricants in the composition can range from about 0.1 to about 5 % per weight of the total composition, preferably form about 0.5 to about 2 % per weight.
- Colorants are adjuvants coloring the composition or dosage form.
- Such adjuvants can include colorants having food quality which are adsorbed on a suitable adsorption means, such as clay or aluminum oxide.
- the amount of the colorant used can vary from about 0.1 to about 5% per weight of the composition and preferably from about 0.1 to about 1% per weight.
- a “pharmaceutically effective amount” of a transglutaminase inhibitor is the amount or activity effective for achieving the desired physiological result, either in cells treated in vitro or in a patient treated in vivo.
- a pharmaceutical effective amount is such an amount which is sufficient for inhibiting, for a certain period of time, one or more of the clinically defined pathological processes associated with transglutaminase 2.
- the effective amount can vary according to the specific compound of the formula (I) and additionally depends on a plurality of factors and conditions related to the subject to be treated and the severity of the disease.
- an inhibitor is to be administered in vivo, factors such as age, weight and health of the patients as well as dose reaction curves and data regarding toxicity obtained from preclinical animal studies are amongst the data to be considered. If the inhibitor in form of the compound of the formula (I) described herein is to be brought in contact with the cells in vivo, a plurality of preclinical in vitro studies would be designed in order to determine parameters such as absorption, half-life, dose, toxicity, etc. Determining a pharmaceutically effective amount for a given pharmaceutically active ingredient is part of the ordinary skills of the one skilled in the art. Examples
- Boc tert-butoxycarbonyl
- BocOSu N-tert-butoxycarbonyloxy-succinimide
- step 6 (according to compound 1-1 b).
- the final product was obtained by deprotection (DCM/TFA) as described above and purified by H PLC.
- step 6 (according to compound 1-1 b).
- the final product was obtained by deprotection (DCM/TFA) as described above and purified by HPLC.
- compound I-76 was performed according to compound 1-1, using (1 R,2R,3R,5S)-(-)-isopinocampheylamine instead of 1-adamantanamine in step 2 (according to ZED3912) and 1 -methyl-1 H-1 ,2, 4-triazole-3-carboxylic acid instead of 1- methyl-1 H-imidazole-5-carboxylic acid in step 6 (according to compound 1-1 b).
- compound 1-82 was performed according to compound 1-81, using 3- (bromomethyl)-l-adamantanol instead of 1-(bromomethyl)adamantane (according to ZED4893) and 4-cyclopropyl-[1 ,2,3]thiadiazole-5-carboxylic acid instead of 1-methyl-
- compound I-83 was performed according to compound 1-81, using 1- bromo-3-(bromomethyl)adamantane instead of 1-(bromomethyl)adamantane (according to ZED4893) and 1 ,2,5-thiadiazole-3-carboxylic acid instead of 1 -methyl-1 H-pyrazole-5- carboxylic acid.
- compound 1-84 was performed according to compound 1-81, using 2- (bromomethyl)adamantane instead of 1-(bromomethyl)adamantane (according to ZED4893) and 4-((tetrahydro-2H-pyran-2-yloxy)methyl)-1 ,2,3-thiadiazole-5-carboxylic acid instead of 1 -methyl-1 H-pyrazole-5-carboxylic acid.
- the tetrahydropyranyl (Thp) protecting group was cleaved by TFA in the final step.
- compound 1-85 was performed according to compound 1-81, using 1- (2-bromoethyl)adamantane instead of 1-(bromomethyl)adamantane (according to ZED4893) and 5-tert-butyl-1 H-pyrrole-3-carboxylic acid instead of 1 -methyl-1 H- pyrazole-5-carboxylic acid.
- compound I-86 was performed according to compound 1-81, using 1- (3-bromopropyl)adamantane instead of 1-(bromomethyl)adamantane (according to ZED4893) and 4-cyano-1 -methyl-1 H-pyrrole-2-carboxylic acid instead of 1 -methyl-1 H- pyrazole-5-carboxylic acid.
- step 6 (according to compound 1-1 b).
- compound 1-93 was performed according to compound 1-1, using 4- aminoadamantane-N,N-dimethyl-1 -carboxamide instead of 1-adamantanamine in step 2 (according to ZED3912) and 1 ,2,3,4-tetrahydronaphthalene-2-carboxylic acid instead of 1 -methyl-1 H-imidazole-5-carboxylic acid in step 6 (according to compound 1-1 b).
- reference compound Ref. 4 was performed according to compound I- 1 , using 2-phenylethylamine instead of 1-adamantanamine in step 2 (according to ZED3912) and nicotinic acid instead of benzofuran-2-carboxylic acid in step 6 (according to compound 1-1 b).
- Example B-1 Inhibitory effect of the compounds according to the invention Transglutaminase assay
- the final concentration of TG2 in the assay is 10 nM.
- 15 mI of inhibitor working dilution are added per well of a 96 well microtiter plate.
- 15 mI of a 2% (v/v) DMSO solution prepared using the buffer mentioned above are added per well.
- IC 50 values are calculated by plotting the enzymatic activity (as percentage from control containing 2% DMSO instead of inhibitor) against the inhibitor concentration. IC 50 is defined as the inhibitor concentration blocking 50 % of initial enzyme activity.
- the inhibitory activity of the inventive compounds in regard to tissue transglutaminase (TG2) is shown in the following table 1 using IC 50 -values.
- Example B-2 logD values of the inventive compounds
- LogD values were determined by means of the well-established shake flask method, measuring the partition of a compound between an octanol and phosphate- buffered saline (PBS, pH 7.4) by HPLC.
- Example B-3 Caco-2 permeability assay of the inventive compounds Permeability coefficients (P app values) were obtained from Caco-2 barrier studies predicting oral/intestinal bioavailability of the tested compounds. The assays were performed by using CacoReadyTM ready-to-use kits from ReadyCell according to the manufacturers protocol.
- A P app ⁇ 1x10 -6 cm/s
- B P app ⁇ 1x10 -6 cm/s ⁇ P app ⁇ 10x10 -6 cm/s
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (22)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2022305117A AU2022305117A1 (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
| KR1020247003631A KR20240028473A (ko) | 2021-06-30 | 2022-06-30 | 트랜스글루타미나아제 억제제 |
| CN202280045270.7A CN117561241B (zh) | 2021-06-30 | 2022-06-30 | 转谷氨酰胺酶的抑制剂 |
| CA3231327A CA3231327A1 (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
| SI202230064T SI4192813T1 (sl) | 2021-06-30 | 2022-06-30 | Zaviralci transglutaminaz |
| US18/572,114 US20240376055A1 (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
| FIEP22741487.7T FI4192813T3 (fi) | 2021-06-30 | 2022-06-30 | Transglutaminaasien estäjiä |
| EP22741487.7A EP4192813B1 (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
| ES22741487T ES2991364T3 (es) | 2021-06-30 | 2022-06-30 | Inhibidores de las transglutaminasas |
| CA3166252A CA3166252C (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
| LTEPPCT/EP2022/068216T LT4192813T (lt) | 2021-06-30 | 2022-06-30 | Transgliutaminazių inhibitoriai |
| DK22741487.7T DK4192813T3 (da) | 2021-06-30 | 2022-06-30 | Inhibitorer af transglutaminaser |
| MX2023015490A MX2023015490A (es) | 2021-06-30 | 2022-06-30 | Inhibidores de las transglutaminasas. |
| PL22741487.7T PL4192813T3 (pl) | 2021-06-30 | 2022-06-30 | Inhibitory transglutaminaz |
| CA3231322A CA3231322A1 (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
| IL309474A IL309474A (en) | 2021-06-30 | 2022-06-30 | transglutaminase inhibitors |
| RS20241217A RS66138B1 (sr) | 2021-06-30 | 2022-06-30 | Inhibitori transglutaminaza |
| JP2023580901A JP7696024B2 (ja) | 2021-06-30 | 2022-06-30 | トランスグルタミナーゼの阻害剤 |
| HRP20241524TT HRP20241524T1 (hr) | 2021-06-30 | 2022-06-30 | Inhibitori transglutaminaza |
| US18/394,766 US20240270715A1 (en) | 2021-06-30 | 2023-12-22 | Inhibitors of transglutaminases |
| ZA2024/00823A ZA202400823B (en) | 2021-06-30 | 2024-01-24 | Inhibitors of transglutaminases |
| JP2024175605A JP2025001006A (ja) | 2021-06-30 | 2024-10-07 | トランスグルタミナーゼの阻害剤 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21182956.9 | 2021-06-30 | ||
| EP21182956 | 2021-06-30 | ||
| EP21183316 | 2021-07-01 | ||
| EP21183316.5 | 2021-07-01 | ||
| US202163217783P | 2021-07-02 | 2021-07-02 | |
| US63/217,783 | 2021-07-02 | ||
| EPPCT/EP2021/086674 | 2021-12-17 | ||
| PCT/EP2021/086674 WO2023110138A1 (en) | 2021-12-17 | 2021-12-17 | Inhibitors of transglutaminases |
| EP2022065430 | 2022-06-07 | ||
| EPPCT/EP2022/065430 | 2022-06-07 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US18/394,766 Continuation US20240270715A1 (en) | 2021-06-30 | 2023-12-22 | Inhibitors of transglutaminases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023275336A1 true WO2023275336A1 (en) | 2023-01-05 |
Family
ID=82547318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2022/068216 Ceased WO2023275336A1 (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
Country Status (20)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12172992B2 (en) | 2022-03-22 | 2024-12-24 | Abbvie Inc. | Pyrimidines for degrading Bruton's tyrosine kinase |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL309476A (en) * | 2021-06-30 | 2024-02-01 | Zedira Gmbh | Transglutaminase inhibitors |
| PL4192813T3 (pl) * | 2021-06-30 | 2024-12-23 | Zedira Gmbh | Inhibitory transglutaminaz |
| DK4192812T3 (da) * | 2021-06-30 | 2024-09-16 | Zedira Gmbh | Transglutaminase-inhibitorer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9434763B2 (en) | 2012-07-17 | 2016-09-06 | Zedira Gmbh | Derivatives of pyridinone as inhibitors for tissue transglutaminase |
| WO2018122419A1 (en) * | 2016-12-27 | 2018-07-05 | Zedira Gmbh | Inhibitors of transglutaminases |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006052755A1 (de) * | 2006-11-08 | 2008-05-15 | N-Zyme Biotec Gmbh | Michaelsysteme als Transglutaminaseinhibitoren |
| IL309476A (en) * | 2021-06-30 | 2024-02-01 | Zedira Gmbh | Transglutaminase inhibitors |
| PL4192813T3 (pl) * | 2021-06-30 | 2024-12-23 | Zedira Gmbh | Inhibitory transglutaminaz |
-
2022
- 2022-06-30 PL PL22741487.7T patent/PL4192813T3/pl unknown
- 2022-06-30 LT LTEPPCT/EP2022/068216T patent/LT4192813T/lt unknown
- 2022-06-30 JP JP2023580901A patent/JP7696024B2/ja active Active
- 2022-06-30 IL IL309474A patent/IL309474A/en unknown
- 2022-06-30 FI FIEP22741487.7T patent/FI4192813T3/fi active
- 2022-06-30 DK DK22741487.7T patent/DK4192813T3/da active
- 2022-06-30 RS RS20241217A patent/RS66138B1/sr unknown
- 2022-06-30 AU AU2022305117A patent/AU2022305117A1/en active Pending
- 2022-06-30 EP EP22741487.7A patent/EP4192813B1/en active Active
- 2022-06-30 CN CN202280045270.7A patent/CN117561241B/zh active Active
- 2022-06-30 US US18/572,114 patent/US20240376055A1/en active Pending
- 2022-06-30 ES ES22741487T patent/ES2991364T3/es active Active
- 2022-06-30 MX MX2023015490A patent/MX2023015490A/es unknown
- 2022-06-30 HR HRP20241524TT patent/HRP20241524T1/hr unknown
- 2022-06-30 KR KR1020247003631A patent/KR20240028473A/ko active Pending
- 2022-06-30 WO PCT/EP2022/068216 patent/WO2023275336A1/en not_active Ceased
- 2022-06-30 HU HUE22741487A patent/HUE068818T2/hu unknown
- 2022-06-30 SI SI202230064T patent/SI4192813T1/sl unknown
-
2023
- 2023-12-22 US US18/394,766 patent/US20240270715A1/en active Pending
- 2023-12-29 CL CL2023003979A patent/CL2023003979A1/es unknown
-
2024
- 2024-01-24 ZA ZA2024/00823A patent/ZA202400823B/en unknown
- 2024-10-07 JP JP2024175605A patent/JP2025001006A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9434763B2 (en) | 2012-07-17 | 2016-09-06 | Zedira Gmbh | Derivatives of pyridinone as inhibitors for tissue transglutaminase |
| WO2018122419A1 (en) * | 2016-12-27 | 2018-07-05 | Zedira Gmbh | Inhibitors of transglutaminases |
| US11072634B2 (en) | 2016-12-27 | 2021-07-27 | Zedira Gmbh | Inhibitors of transglutaminases |
Non-Patent Citations (7)
| Title |
|---|
| AYMAN EL-FAHAMFERNANDO ALBERICIO: "Peptide Coupling Reagents, More than a Letter Soup", CHEMICAL REVIEWS, vol. 111, no. 11, 2011, pages 6557 - 6602, XP055708830, DOI: 10.1021/cr100048w |
| BUCHOLD, C.HILS, M.GERLACH, U.WEBER, JPELZER, C.HEIL, A.AESCHLIMANN, D.PASTERNACK, R.: "Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease", CELLS, vol. 11, 2022, pages 1667, Retrieved from the Internet <URL:https://doi.org/10.3390/ce!!s11101667> |
| BUCHOLD, C.HILS, M.GERLACH, UWEBER, J.PELZER, C.HEIL, AAESCHLIMANN, DPASTERNACK, R: "Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease.", CELLS, vol. 11, 2022, pages 1667, Retrieved from the Internet <URL:https://doi.org/10.3390/ce!!s11101667> |
| J.M. WODZINSKA, MINI-REVIEWS IN MEDICAL CHEMISTRY, vol. 5, 2005, pages 279 - 292 |
| LORAND ET AL., ANAL BIOCHEM, vol. 44, 1971, pages 221 - 31 |
| SUBBAIAH ET AL., J. MED. CHEM., vol. 64, no. 19, 2021, pages 14046 - 14128 |
| TSE ET AL., J. MED. CHEM., vol. 63, 2020, pages 11585 - 11601 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12172992B2 (en) | 2022-03-22 | 2024-12-24 | Abbvie Inc. | Pyrimidines for degrading Bruton's tyrosine kinase |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024524458A (ja) | 2024-07-05 |
| CN117561241B (zh) | 2025-10-28 |
| LT4192813T (lt) | 2024-11-11 |
| US20240376055A1 (en) | 2024-11-14 |
| CN117561241A (zh) | 2024-02-13 |
| SI4192813T1 (sl) | 2025-03-31 |
| ES2991364T3 (es) | 2024-12-03 |
| FI4192813T3 (fi) | 2024-11-07 |
| HUE068818T2 (hu) | 2025-01-28 |
| RS66138B1 (sr) | 2024-11-29 |
| PL4192813T3 (pl) | 2024-12-23 |
| EP4192813A1 (en) | 2023-06-14 |
| EP4192813B1 (en) | 2024-08-14 |
| CL2023003979A1 (es) | 2024-06-14 |
| ZA202400823B (en) | 2025-05-28 |
| JP7696024B2 (ja) | 2025-06-19 |
| KR20240028473A (ko) | 2024-03-05 |
| MX2023015490A (es) | 2024-01-19 |
| US20240270715A1 (en) | 2024-08-15 |
| IL309474A (en) | 2024-02-01 |
| JP2025001006A (ja) | 2025-01-07 |
| AU2022305117A1 (en) | 2023-12-14 |
| DK4192813T3 (da) | 2024-09-02 |
| HRP20241524T1 (hr) | 2025-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4192813A1 (en) | Inhibitors of transglutaminases | |
| FI114795B (fi) | Aroyylipiperidiinijohdannaiset | |
| HRP20030748A2 (en) | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | |
| JP2010509195A (ja) | トランスグルタミナーゼ阻害剤としてのマイケル・システム | |
| JP2015529645A (ja) | 組織トランスグルタミナーゼ阻害剤としてのピリジノン誘導体 | |
| EP4192814B1 (en) | Inhibitors of transglutaminases | |
| WO2000000470A1 (en) | Amino acid derivatives and drugs containing the same as the active ingredient | |
| EP4192812B1 (en) | Inhibitors of transglutaminases | |
| JP2007527904A (ja) | グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−2−カルボン酸ヒドラジド化合物 | |
| TW475930B (en) | Novel compound, its use and pharmaceutical composition comprising it | |
| WO2001040204A1 (en) | 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient | |
| HK40095238A (en) | Inhibitors of transglutaminases | |
| HK40095238B (en) | Inhibitors of transglutaminases | |
| JP2007527903A (ja) | インドール−2−カルボン酸ヒドラジド化合物 | |
| EP3875456A1 (en) | Hetero-bifunctional proteolysis-targeting chimeras (protacs) for the selective degradation of fk506-binding proteins (fkbps) | |
| EA048648B1 (ru) | Ингибиторы трансглутаминаз | |
| HK40095266A (en) | Inhibitors of transglutaminases | |
| HK40095266B (en) | Inhibitors of transglutaminases | |
| CA3231322A1 (en) | Inhibitors of transglutaminases | |
| HK40095264A (en) | Inhibitors of transglutaminases | |
| HK40095264B (en) | Inhibitors of transglutaminases | |
| KR20240035404A (ko) | 트랜스글루타미나제 억제제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22741487 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2022741487 Country of ref document: EP Effective date: 20230307 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 806076 Country of ref document: NZ Ref document number: 2022305117 Country of ref document: AU Ref document number: AU2022305117 Country of ref document: AU |
|
| ENP | Entry into the national phase |
Ref document number: 2022305117 Country of ref document: AU Date of ref document: 20220630 Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/015490 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 309474 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202317087075 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202280045270.7 Country of ref document: CN Ref document number: 2301008469 Country of ref document: TH |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202393429 Country of ref document: EA |
|
| ENP | Entry into the national phase |
Ref document number: 2023580901 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12023553524 Country of ref document: PH |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023027197 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 20247003631 Country of ref document: KR Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: P-2024/1217 Country of ref document: RS |
|
| WWG | Wipo information: grant in national office |
Ref document number: P-2024/1217 Country of ref document: RS |
|
| ENP | Entry into the national phase |
Ref document number: 112023027197 Country of ref document: BR Kind code of ref document: A2 Effective date: 20231221 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 202280045270.7 Country of ref document: CN |